Malecare Responds to the New York Times About the High Costs of Advanced Prostate Cancer Treatments

Darryl, the Malecare Executive Director, posted an organizational response to yesterday's New York Times Article on the newly approved advanced prostate cancer drugs and their economic impact. I thought that I would share his insightful post with everyone. "We can easily price commodities and drugs to whatever the market will bare, but how do we [...]

The High Cost of Prostate Cancer Treatments – How Telling Are the Comments

Today’s New York Times carried a front page article about the high cost of the new prostate cancer treatments. This article seems to be the talk of the town and the talk (based on the comments that have been entered on-line) has been anything but positive. Unfortunately, many of the comments have made with the [...]